Transdermal delivery of erythromycin lactobionate-implications for the therapy of gastroparesis

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 3, 1997, Pages 589-592

  Brand, R M ^a   Lof, J ^a   Quigley, E M M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN LACTOBIONATE;

ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ABSORPTION; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030853472     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00165.x     Document Type: Article

References (15)

1. Quigley EMM. Gastric and small intestinal motility in health and disease. Gastroenterol Clin N Am 1996; 25: 113-45.
2. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37: 543-51.
3. Edwards LL, Quigley EM, Pleiffer RF. Gastrointestinal dysfunction in Parkinson's disease: Frequency and pathophysiology. Neurology 1992; 42: 726-32.
4. Quigley EMM. The clinical pharmacology of motilily disorders: the perils (and pearls) of prokinesia. Gastroenterology 1994; 106: 1112-20.
5. Guy RH, Hadgraft JJ. Transdermal drug delivery: a perspective. J Controlled Rel 1987; 4: 237-51.
6. Pitt CG. The controlled parenteral delivery of polypeptides and proteins. Int J Pharm 1990; 59: 173-96.
7. Berner H, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994; 26: 121-34.
8. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, VanTrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: G470-4.
9. Tack J, Janssens J, VanTrappen G, et al. Effect of erythromycin on gastric motility in controls and diabetic gastroparesis. Gastroenterology 1992; 103: 72-9.
10. Camilleri M. The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol 1993; 88: 169-71.
11. Klingman AM, Christopher E. Preparation of isolated sheets of human stratum corneum. Arch Derm 1963; 88: 70-3.
12. Skelly JP, Shah VP, Maibach HI, et al. FDA and AAPS report of the workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res 1987; 4: 265-7.
13. Stubbs C, Haigh JM, Kanfer I. Determination of erythromycin in serum and urine by high-performance liquid chromatography with ultraviolet detection. J Pharm Sci 1985; 74: 1126-8.
14. Elias PM. Epidermal lipids and desquamation. J Invest Dermatol 1983; 80: S44-9.
15. Walker RB, Smith EW. The role of percutaneous penetration enhancers. Adv Drug Del Rev 1996; 18: 295-301.